Discngine develops software applications for the research departments of life sciences companies, specializing in work related to active molecule discovery. Established in 2004 by two of Pfizer’s research alumni and led by founder and CEO Eric Le Roux, the company is based in Paris. Its offering evolved from custom software to licenses for software components and business solutions. Discngine is running a two-year R&D program, 3decision®, to build a collaborative large-scale three-dimensional data management application for biomolecules; the program began in March 2018. The R&D aims to enable users to consult, manage, and communicate around structural data for a wide range of biomolecules and to support a commercial launch. Clients include world leaders in the pharmaceutical, cosmetics, and agrochemical industries. The company plans to focus on offering catalog products through SaaS and cloud-based subscription models and has secured external funding to support the program. Discngine develops software applications for research departments of life sciences companies, specializing in workflows related to active molecule discovery. The company has historically offered custom software and licensed components and business solutions, and is now shifting to catalog products via SaaS and cloud subscriptions. It is collaborating with Dassault Systèmes BIOVIA to distribute its first two SaaS solutions and plans to launch additional life-sciences research solutions in 2018. Discngine was founded in 2004 by two former Pfizer researchers and is led by CEO Eric Le Roux. The company currently employs 38 people and counts world leaders in the pharmaceutical, cosmetics and agrochemical industries among its clients. The recent financing is intended to accelerate product development and commercialization and to support international expansion.

Total raised

$2M

Funding rounds

3

Latest round

Debt Financing

Latest activity

May 2018